Currently, a Phase II clinical trial is evaluating the IL‐6 antibody (tocilizumab) combined with chemotherapy for pancreatic cancer, aiming to improve treatment response and alleviate cachexia [702]. The gene discussed is IL6; the disease is familial pancreatic carcinoma.